PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma
The ability to make early adjustments to treatment has the potential to improve survival.
Non-Hodgkin Lymphoma
Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.
Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides
The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.
Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma
Palonosetron effectively prevents and manages delayed CINV in patients with non-Hodgkin lymphoma.
Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape
[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.
Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
The patient’s history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.
NHL: Adolescent BMI, Height Linked With Subtype Risks
Higher body weight and increased height during adolescence increase the risk for developing certain subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.
No Risk of Second Primary Malignancies in Patients With NHL Receiving Rituximab
Survivors of non-Hodgkin lymphoma (NHL) exposed to rituximab do not have an increased risk for developing second primary malignancies.
Timing Matters for Pegfilgrastim Administration
The incidence of febrile neutropenia was significantly higher among patients who received pegfilgrastim prophylaxis on the same day.
Breakthrough Advance Announced in International Blood Cancer Drug Trial
Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.
-
Loading...
-
Loading...
Next post in Lymphoma
